INDIAGLYCO India Glycols Q1 FY26 results (Apr–Jun 2025) and concall
India Glycols delivered a strong Q1 FY26, primarily driven by robust performance in its Bio-Fuel and Potable Spirits segments, which saw significant revenue and profit growth. Overall margins expanded, despite some pressures in the Chemicals and Ennature Biopharma segments. The company is also advancing its demerger plans and strategic partnerships, focusing on premiumization and market expansion, while maintaining a conservative CapEx and debt reduction strategy.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 961 | 975 | 863 | 1,040 |
| EBITDA | 116 | 124 | 144 | 148 |
| Net profit | 39 | 44 | 50 | 53 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
